Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · IEX Real-Time Price · USD
1.530
-0.020 (-1.29%)
At close: Jul 17, 2024, 4:00 PM
1.550
+0.020 (1.31%)
After-hours: Jul 17, 2024, 7:50 PM EDT

Company Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.

Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.

The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.

It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities.

The company is headquartered in Houston, Texas.

Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 2
CEO David J. Arthur M.B.A.

Contact Details

Address:
2450 Holcombe Blvd, Suite J-608
Houston, Texas 77021
United States
Phone 346-772-0346
Website salariuspharma.com

Stock Details

Ticker Symbol SLRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001615219
CUSIP Number 79400X107
ISIN Number US79400X3052
Employer ID 46-5087339
SIC Code 2834

Key Executives

Name Position
David J. Arthur M.B.A. Chief Executive Officer, President and Director
Mark J. Rosenblum CPA Executive Vice President of Finance and Chief Financial Officer
Dr. Nadeem Q. Mirza M.D., M.P.H. Senior Vice President of Clinical Development
Dr. Daniela Y. Santiesteban Director of Targeted Protein Degradation Program

Latest SEC Filings

Date Type Title
Jul 11, 2024 8-K Current Report
Jun 17, 2024 424B5 Filing
Jun 17, 2024 8-K Current Report
Jun 14, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
Apr 22, 2024 10-K/A [Amend] Annual report
Mar 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 26, 2024 DEF 14A Other definitive proxy statements
Mar 22, 2024 10-K Annual Report
Mar 20, 2024 DFAN14A Filing